The Effects Of Early SOX Chemotherapy On Postoperative Gastric Cancer Patients Undergoing Accelerated Rehabilitation Surgery

Objective:Previous studies found that chemotherapy can effective control tumor growth when it is performed 2 weeks after gastric cancer surgery.However,limited with the traditional recovery strategy after surgery,patients always have chemotherapy intolerance at that time point.Research has shown that adoption of Enhanced Recovery after Surgery(ERAS)lead to patients experience faster recovery,shortened hospital stay,and finally make the chemotherapy 2 weeks after surgery possible.In this study,we examined the effects of early SOX chemotherapy on the short-term clinical outcomes of patients with gastric cancer after surgery.Method:Sixty patients who met the inclusion criteria were randomly divided into the Experimental group,ERAS group,and Control group,with 20 people in each group.The Experimental group which managed by ERAS protocol after surgery,and patients discharged about Ⅰ week after surgery and started chemotherapy around 2 weeks.The ERAS group was managed by ERAS protocol after surgery,the patients in this group were discharged about 1 week after surgery and started chemotherapy around 4 weeks.The Control group was treated according to the traditional strategy.The patients were discharged about 2 weeks after surgery and started chemotherapy around 4 weeks.The SOX regimen was chosen as postoperative chemotherapy regimen and was performed for 8 cycles in total.Follow-up was continued for six months after the end of chemotherapy.The detailed clinical data of each group of patients,postoperative pathological staging,postoperative exhaust time,postoperative complications,half-fluid time after eating,occurrence of adverse reactions during chemotherapy,and tumor recurrence rate were recorded separately.Results:There was no significant difference on the basic conditions of age,BMI,and gender among the three groups of patients(p>0.05).After the operation,there was no significant difference between the Experimental group and the ERAS group on the postoperative exhaust time and postoperative semifluid food intake time(p>0.05),but these two groups were significantly better than the Control group(p<0.05).All groups showed similar postoperative pathological staging(p>0.05).The incidence of postoperative complications was not significantly different between these three groups(p>0.05).During the treatment of chemotherapy,there was no difference in the incidence of adverse reactions to chemotherapy between the ERAS group and the Control group,which was slightly better than the Experimental group,but the difference was not statistically significant(p>0.05).The recurrence rate of patients at 1 year after operation was significantly better in the Experimental group than that in the ERAS group and the Control group,and the difference was statistically significant(p<0.05).Conclusion:The intervention of ERAS can enable patients with gastric cancer to recover gastrointestinal function earlier,and early treatment with SOX chemotherapy will not increase the adverse reactions of patients during chemotherapy,and can reduce the recurrence rate of patients after 1 year.